Phase IIb primary vaccination study to evaluate non-inferiority and persistence of the immune response of GSK Biologicals MenACWY conjugate vaccine (intramuscularly) vs Mencevax ACWY (subcutaneously) to healthy subjects (11-55 Years of age).

Trial Profile

Phase IIb primary vaccination study to evaluate non-inferiority and persistence of the immune response of GSK Biologicals MenACWY conjugate vaccine (intramuscularly) vs Mencevax ACWY (subcutaneously) to healthy subjects (11-55 Years of age).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
    • 02 Aug 2012 Actual end date (1 May 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top